Gregory Pokrywka
Internal Medicine · Towson, MDNPI 1417082322
Payments from drug & device makers
Across 878 payments — averaging $466.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$184K
- Amgen$84K
- Esperion Therapeutics, Inc.$51K
- Novartis$29K
- Amryt Pharma Holdings Ltd$15K
- Regeneron Healthcare Solutions, Inc.$12K
- plus $35K from 31 others
What the payments were for
- Consulting fees$7,4282%
- Speaking & faculty fees$318,79285%
- Travel & lodging$31,5918%
- Food & beverage$19,3505%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 242 | $183,821 |
| Amgen(2 entities) | 147 | $83,833 |
| Esperion Therapeutics, Inc. | 92 | $51,293 |
| Novartis | 82 | $29,459 |
| Amryt Pharma Holdings Ltd | 21 | $14,537 |
| Regeneron Healthcare Solutions, Inc. | 51 | $11,636 |
| Medicure Pharma Inc. | 10 | $10,159 |
| Sanofi-aventis U.S. LLC | 7 | $6,611 |
| Merck | 16 | $6,417 |
| Ionis Pharmaceuticals, Inc. | 2 | $4,909 |
| Argenx US, Inc. | 1 | $2,250 |
| Lilly USA, LLC | 43 | $939 |
| Novo Nordisk | 36 | $669 |
| AstraZeneca(2 entities) | 17 | $376 |
| Chiesi USA, Inc. | 2 | $323 |
| Orexo US, Inc. | 18 | $308 |
| Kowa Pharmaceuticals America, Inc. | 13 | $297 |
| Madrigal Pharmaceuticals | 5 | $281 |
| Alkermes, Inc. | 17 | $272 |
| Boehringer Ingelheim | 12 | $261 |
| Bayer | 6 | $185 |
| Regeneron | 7 | $182 |
| Kaneka Medical America LLC | 1 | $165 |
| USWM, LLC | 3 | $99 |
| MDD US Operations, LLC | 4 | $83 |
| AbbVie(2 entities) | 4 | $80 |
| Acerus Pharmaceuticals Corporation | 4 | $73 |
| Abbott | 3 | $55 |
| Travere Therapeutics, Inc. | 3 | $43 |
| Indivior Inc. | 2 | $39 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Antares Pharma, Inc. | 1 | $23 |
| Vivus LLC | 1 | $22 |
| Corcept Therapeutics | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Cleerly, Inc. | 1 | $17 |
| Aegerion Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$180,065
- Repatha$81,475
- NEXLIZET$49,815
- NEXLETOL$49,815
- PRALUENT$17,079
- JUXTAPID$14,587
- ZYPITAMAG (pitavastatin)$7,008
- HMG-CoA reductase inhibitor.$3,000
- VYVGART HYTRULO$2,250
- LEQVIO$509
- REZDIFFRA$122
- Kerendia$109
How this compares
$409,800 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvkeezaEvinacumab-Dgnb | 24 | $732,908 |
| Repatha SureclickEvolocumab | 258 | $216,324 |
| MounjaroTirzepatide | 123 | $148,411 |
| VascepaIcosapent Ethyl | 156 | $134,971 |
| Praluent PenAlirocumab | 98 | $71,193 |
| NexlizetBempedoic Acid/Ezetimibe | 66 | $69,209 |
| OzempicSemaglutide | 51 | $57,246 |
| FarxigaDapagliflozin Propanediol | 22 | $33,900 |
| TrulicityDulaglutide | 21 | $28,582 |
| Icosapent Ethyl | 48 | $19,333 |
| NexletolBempedoic Acid | 23 | $18,740 |
| Ezetimibe | 246 | $11,639 |
| Repatha SyringeEvolocumab | 15 | $11,499 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $5,795 |
| Rosuvastatin Calcium | 205 | $5,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Evkeeza | $11,636 | $732,90824 claims |
| Lilly USA, LLCMounjaro, Trulicity | $939 | $176,993144 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $51,293 | $87,94989 claims |
| Novo NordiskOzempic | $669 | $57,24651 claims |
| AstraZenecaFarxiga | $376 | $33,90022 claims |
| Orexo US, Inc.Zubsolv | $308 | $5,79513 claims |
| Indivior Inc.Suboxone | $39 | $3,17621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Towson
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.